CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

18 Dec 2023 06:30:03 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

05 Dec 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

04 Dec 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

16 Nov 2023 08:05:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

08 Nov 2023 16:11:02 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

02 Nov 2023 10:37:31 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

30 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

26 Oct 2023 15:19:11 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

23 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

19 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

16 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

13 Oct 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

18 Sep 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

16 Aug 2023 10:56:47 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

14 Aug 2023 08:05:10 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

09 Aug 2023 16:17:05 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

19 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

20 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

01 Jun 2023 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

30 May 2023 08:03:00 By Nasdaq GlobeNewswire